deCODE genetics, Inc. And Celera Corporation Partner to Expand Use of deCODE Risk Markers for Heart Attack, Stroke and Diabetes

REYKJAVIK, Iceland & ALAMEDA, Calif.--(BUSINESS WIRE)--deCODE genetics (NASDAQ:DCGN) and Celera Corporation (NASDAQ:CRA) today announced the signing of agreements under which deCODE has granted Celera non-exclusive worldwide licenses to deCODE’s genetic markers for increased risk of major cardiovascular and metabolic diseases, including heart attack, stroke, atrial fibrillation (AF) and type 2 diabetes (T2D). These markers can be incorporated into laboratory tests for assessing and managing individual risk of these diseases.

Back to news